Abstract:OBJECTIVE:To explore the polymorphism of cholesteryl ester transfer protein (CETP) gene -629C/A among the coronary heart disease (CHD) Han population of Tianjin area and evaluate the influences of genetic factors on atorvastatin therapeutic effects and clinical outcomes in pharmacogenomics and provide theoretical rationales for individualized treatment.METHODS:A total of 332 angiographically confirmed CHD patients at Tianjin Chest Hospital were recruited from October 2010 to July 2011. The CETP gene promoter polymorphism at position -629 was determined by polymerase chain reaction-restricted fragment length polymorphism (PCR-RFLP). The serum level of CETP was determined by enzyme-linked immunosorbent assay (ELISA).Lipid levels were determined at baseline and 12 months post-treatment with 20 mg/d atorvastatin in all patients. Clinical follow-up were performed for more than 1 year (range, 12-23 months). And major adverse cardiac events (MACE, including death, non-fatal infarction, revascularization and stroke) were analyzed. The Kaplan-Meier Log-rank test was used to compare MACE-free survival between different genotypes.RESULTS:(1) The frequencies of variant -692A allele was 0.476, AA genotype showed reduced CETP levels and higher HDL-C levels compared with CC and CA genotypes. But it did not reach statistical significance (F = 0.893, P = 0.411 and F = 1.279, P = 0.282 respectively). Although a negative trend correlation existed between serum levels of HDL-C and CETP, it did not reach statistical significance (r = -0.151, P = 0.081) . (2) After 12-month therapy of atorvastatin, CC genotype was shown to be associated with higher LDL-C, LP(a) reduction and HDL-C elevation in response to atorvastatin compared with CA and AA genotype.LDL-C levels decreased 43.5% in CC homozygotes, 25.5% in CA heterozygotes and 11.7% in AA homozygotes (P = 0.001).HDL-C levels increased 9.2% in CC homozygotes, 6.8% in CA heterozygotes and 5.5% in AA homozygotes.However the changes of HDL-C levels in three genotypes showed no significant difference (P = 0.412). (3) There was a 7.83% incidence of MACE after a mean follow-up of (18.66 ± 5.99) months. The outcomes were death (n = 3, 0.90%), non-fatal infarction (n = 7, 2.11%), revascularization (n = 13, 3.92%) and stroke (n = 3, 0.90%). The cumulative MACE free survival rates were 96.2% , 92.1% and 87.3% in CC, CA and AA genotypes respectively (Log-rank P = 0.444).CONCLUSION:Variant AA genotype shows a higher level of HDL-C s and a lowered level of CETP.However CC genotype offers a better benefit of statin therapy associated with lowered levels of LDL-C and LP(a). And the long-term clinical prognosis is not affected among three genotypes.

[Effects of ApoE gene polymorphism on the efficacy of atorvastatin in the treatment of hyperlipidemia]

Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases.

Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke

Effects of ApoE polymorphism on plasma lipid levels and coronary disease

The Relationship Between ApoE Gene Polymorphism and Lipid Parameters

[Influence of ApoE gene polymorphisms on therapeutic effects of lipid-lowering statins among patients with ischemic cerebral infarction]

Mechanism of action of apolipoprotein E genetic polymorphism on the efficacy of fluvastatin

Relationship between apolipoprotein E polymorphism and coronary heart disease

Relationship between Apolipoprotein E Genotype and Lipoprotein Profile in Patients with Coronary Heart Disease

Correlation between apolipoprotein E gene polymorphism and plasma lipid level

Progress in Efficacy of Apolipoprotein E Polymorphisms on Antihyperlipidemic

Influence of Apolipoprotein E Polymorphism on Postprandial Triglyceride Metabolism in Patients with Coronary Heart Disease

Influence of apolipoprotein E gene polymorphisms on coronary artery disease in patients undergoing coronary angiography

Association of Apolipoprotein E Polymorphism with Plasma Lipids and Atherosclerosis

Clinical study of the association between apoE polymorphism and lipid metabolism of patients with CHD

[Effect of Apolipoprotein E Gene Plasma Levels of Lipids, Lipoproteins, Apolipoproteins and Its Relation with Coronary Heart Disease].

Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia

Influence of PCSK9 gene E670G polymorphism on the risk of atherosclerotic coronary heart disease and plasma lipid level

Effect of Apolipoprotein E Gene Polymorphism on Lipid and Essential Hypertension

Relationship Between the Cholesterol Ester Transfer Protein TaqIB Polymorphism and the Lipid-Lowering Effect of Atorvastatin in Patients with Coronary Atherosclerotic Heart Disease.

[Effects of Genetic Variations of Cholesteryl Ester Transfer Protein on Atorvastatin Treatment Efficacy and Clinical Outcomes in Patients with Coronary Artery Disease].